Cellosaurus UACC-893 (CVCL_1782)

Cell line name UACC-893
Synonyms UACC 893; UACC893; University of Arizona Cell Culture-893
Accession CVCL_1782
Resource Identification Initiative To cite this cell line use: UACC-893 (RRID:CVCL_1782)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: ICBP43 breast cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Doubling time: 120 hours (PubMed=1674877).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Invasive ductal carcinoma, not otherwise specified (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12
D13S31713
D16S5399,13
D18S5117,18
D21S1128,30.2
D3S135816
D5S81812
D7S82011
D8S117913
FGA22,25
Penta D9,12
Penta E13,17
TH016,9.3
TPOX8
vWA16,17
Web pages http://lincs.hms.harvard.edu/resources/reagents/icbp43/
http://tcpaportal.org/mclp/
Publications

PubMed=1674877; DOI=10.1038/bjc.1991.164
Meltzer P.S., Leibovitz A., Dalton W.S., Villar H., Kute T., Davis J., Nagle R., Trent J.M.
Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification.
Br. J. Cancer 63:727-735(1991)

PubMed=9778046; DOI=10.1038/sj.onc.1202086
Rice J.C., Massey-Brown K.S., Futscher B.W.
Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
Oncogene 17:1807-1812(1998)

PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B
Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J., Larsson C.
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Genes Chromosomes Cancer 28:308-317(2000)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=20070913; DOI=10.1186/1471-2407-10-15
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15-15(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L., Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-1902
Cell line databases/resources CCLE; UACC893_BREAST
Cosmic-CLP; 909778
GDSC; 909778
IGRhCellID; UACC893
LINCS_HMS; 50557
LINCS_LDP; LCL-1320
Ontologies BTO; BTO:0003443
CLO; CLO_0009468
EFO; EFO_0002385
Biological sample resources BioSample; SAMN03472115
Chemistry resources ChEMBL-Cells; CHEMBL3308807
ChEMBL-Targets; CHEMBL1075605
Gene expression databases GEO; GSM69197
GEO; GSM73728
GEO; GSM344384
GEO; GSM344434
GEO; GSM350529
GEO; GSM481326
GEO; GSM783959
GEO; GSM887728
GEO; GSM888822
GEO; GSM1053703
GEO; GSM1172907
GEO; GSM1173003
GEO; GSM1215273
GEO; GSM1670564
Polymorphism and mutation databases Cosmic; 687502
Cosmic; 871151
Cosmic; 894092
Cosmic; 897416
Cosmic; 904397
Cosmic; 909778
Cosmic; 1017162
Cosmic; 1018469
Cosmic; 1046943
Cosmic; 1044233
Cosmic; 1047718
Cosmic; 1136362
Cosmic; 1287903
Cosmic; 1289420
Cosmic; 1523773
Cosmic; 1603228
Cosmic; 2165015